Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis

Catalyst Pharmaceuticals, Inc. (CPRX) Healthcare & Pipeline Overview

Catalyst Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapies for rare neuromuscular and neurological diseases, with a strong emphasis on patient-centric solutions and a robust pipeline that positions it well within the biotechnology sector.

What Is the Investment Thesis for CPRX?

The company has achieved a profit margin of 36.4% and a gross margin of 85.2%, highlighting operational efficiency and strong demand for its products. With a market capitalization of $3.85B and a P/E ratio of 17.49, Catalyst is well-positioned for growth as it expands its therapeutic indications and explores new markets. Key growth catalysts include the ongoing development of Firdapse for additional indications and potential collaborations that may enhance its market reach. The company’s focus on rare diseases, which have limited competition, provides a strategic advantage, allowing for sustained revenue growth. However, investors should remain aware of potential risks, including regulatory challenges and market competition from other biotechnology firms.

Based on FMP financials and quantitative analysis

CPRX Key Highlights

Market capitalization of $3.85B, reflecting strong investor confidence in growth prospects.

• Profit margin of 36.4%, indicating effective cost management and strong product demand.
• Gross margin of 85.2%, significantly higher than the industry average, showcasing operational efficiency.
• P/E ratio of 17.49, suggesting a reasonable valuation relative to earnings.
• Beta of 0.66, indicating lower volatility compared to the broader market.

Who Are CPRX's Competitors?

CPRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CPRX's Key Strengths?

Strong product portfolio with FDA-approved therapies for rare diseases.

• High gross margin of 85.2%, indicating operational efficiency.
• Established partnerships with leading pharmaceutical companies.

What Are CPRX's Weaknesses?

Limited product range focused primarily on rare diseases.

• Dependence on a small number of key products for revenue.
• Potential challenges in scaling operations for international markets.

What Could Drive CPRX Stock Higher?

CPRX catalyst: Expansion of Firdapse indications for additional neurological disorders expected to be submitted for FDA review in 2026.

• Strategic collaborations with BioMarin Pharmaceutical Inc. and Endo Ventures Limited to develop new therapies and enhance market reach.
• Continuous investment in R&D to support the development of innovative treatments for rare diseases.

What Are the Key Risks for CPRX?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Insider selling — insiders were net sellers of roughly $334.8M recently.
• Regulatory hurdles that could delay the approval of new therapies.
• Competitive pressures from other biotechnology firms targeting the same rare disease markets.
• Market volatility that may impact funding for research and development initiatives.

What Are the Growth Opportunities for CPRX?

• Expansion of Firdapse indications: Catalyst is actively pursuing the development of Firdapse for additional indications, including MuSK antibody positive myasthenia gravis and spinal muscular atrophy type 3. The market for myasthenia gravis treatments is expected to grow to $3.5 billion by 2027, driven by increasing diagnosis rates and treatment options. This expansion could significantly enhance Catalyst's revenue streams over the next few years.
• Strategic partnerships: Catalyst has established collaborative agreements with BioMarin Pharmaceutical Inc. and Endo Ventures Limited, which could facilitate the development and commercialization of new therapies. These partnerships not only provide financial support but also enhance Catalyst's research capabilities and market access, potentially leading to new product launches within the next 2-3 years.
• Geographic expansion: Currently focused on the U.S. market, Catalyst has opportunities to expand its product offerings internationally. The global rare disease market is growing rapidly, and entering new markets could provide substantial revenue growth. Catalyst could target Europe and Asia, where the demand for rare disease treatments is increasing, potentially leading to new revenue streams by 2026.
• Investments in R&D: Catalyst's commitment to research and development is a key growth driver. By investing in innovative therapies and expanding its pipeline, the company can capitalize on the growing market for rare disease treatments. Increased R&D spending could lead to new product approvals and market entries, enhancing its competitive positioning over the next few years.
• Patient-centric initiatives: Catalyst's focus on patient needs and support programs can drive brand loyalty and increase market penetration. By enhancing patient access to its therapies and providing comprehensive support, Catalyst can strengthen its market position and potentially increase sales by fostering long-term relationships with healthcare providers and patients.

What Threats Does CPRX Face?

• Regulatory challenges in drug approvals and market access.
• Competition from other biotechnology firms targeting similar markets.
• Market volatility affecting funding and investment in R&D.

What Are CPRX's Competitive Advantages?

• Strong intellectual property portfolio protecting its proprietary drugs.
• Focused on rare diseases, resulting in less competition and higher pricing power.
• Established relationships with healthcare providers and patient advocacy groups enhance market access.

What Does CPRX Do?

Founded in 2002, Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida. Initially known as Catalyst Pharmaceutical Partners, Inc., the company rebranded in May 2015 to reflect its commitment to developing therapies for rare and debilitating diseases. Catalyst specializes in addressing the unmet medical needs of patients suffering from chronic neuromuscular and neurological disorders. Its lead product, Firdapse, is an amifampridine phosphate tablet approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder. Additionally, Catalyst offers Ruzurgi, specifically formulated for pediatric patients with LEMS. The company is also advancing Firdapse for other indications, including MuSK antibody positive myasthenia gravis and spinal muscular atrophy type 3. Catalyst has established strategic partnerships, including licensing agreements with BioMarin Pharmaceutical Inc. and collaboration with Endo Ventures Limited for the development of generic Sabril tablets. With a dedicated workforce of 181 employees, Catalyst is committed to enhancing the quality of life for patients through innovative therapies and has positioned itself as a leader in the niche market of rare diseases.

What Products and Services Does CPRX Offer?

• Develops and commercializes therapies for rare neuromuscular and neurological diseases.
• Offers Firdapse, an FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome.
• Provides Ruzurgi, a treatment specifically for pediatric patients with LEMS.
• Engages in research for additional therapeutic indications for Firdapse.
• Establishes strategic partnerships for drug development and commercialization.
• Focuses on patient-centric solutions to enhance treatment accessibility.

How Does CPRX Make Money?

• Generates revenue primarily through the sale of its proprietary drugs, Firdapse and Ruzurgi.
• Engages in licensing agreements and collaborations for drug development with other pharmaceutical companies.
• Invests in research and development to expand its product pipeline and therapeutic indications.
• Focuses on niche markets with high unmet medical needs to establish a competitive advantage.

What Industry Does CPRX Operate In?

The biotechnology industry is experiencing significant growth, driven by advancements in medical research and the increasing prevalence of rare diseases. Catalyst Pharmaceuticals, Inc. operates in a competitive landscape that includes peers such as Cidara Therapeutics, Inc. (CDTX), Scholar Rock Holding Corporation (SRRK), and Apellis Pharmaceuticals, Inc. (APLS). The focus on rare diseases allows Catalyst to carve out a niche with less competition, positioning it favorably within the broader healthcare sector as demand for specialized treatments continues to rise.

Who Are CPRX's Key Customers?

• Patients suffering from rare neuromuscular and neurological diseases.
• Healthcare providers and specialists prescribing treatments for LEMS and related conditions.
• Pharmaceutical partners involved in collaborative drug development and commercialization.

Over the past six months, Catalyst Pharmaceuticals, Inc. insiders filed 100 SEC Form 4 transactions — 100 sales and 0 purchases. On net that is roughly 16.5M shares disposed (about $334.8M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Catalyst Pharmaceuticals, Inc.

Revenue for Catalyst Pharmaceuticals, Inc. came in at $149.4M during Mar 2026, a 2.1% contraction versus the preceding quarter. The company recorded net income of $63.7M, with diluted EPS of $0.50. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, CPRX averaged $0.44 in diluted EPS.

CPRX Valuation & Market Position

With a $3.85B market cap, Catalyst Pharmaceuticals, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $31.50 to $32.00, with a consensus of $31.75. At the current price of $31.49, that implies approximately 1% upside potential.

Return on equity for Catalyst Pharmaceuticals, Inc. stands at 23.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.3%, showing how much profit it generates from its asset base. CPRX trades at a trailing price-to-earnings ratio of 17.49, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.8%, the inverse of the P/E and a quick read on earnings relative to price.

Catalyst Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 20.00 places it in the safe zone, indicating low near-term bankruptcy risk.

Catalyst Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.4% above estimates on average.

Wall Street analysts project Catalyst Pharmaceuticals, Inc. revenue of about $635.1M for fiscal 2026, with EPS near $1.95.

Company Profile

Catalyst Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Coral Gables, US. The company is led by CEO Richard John Daly. CPRX has traded publicly since 2006.

CPRX Financials

CPRX Latest News

Catalyst Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources